[1]
|
Deutschländer, A.B., Ross, O.A., Dickson, D.W. and Wszolek, Z.K. (2017) Atypical Parkinsonian Syndromes: A General Neurologist’s Perspective. European Journal of Neurology, 25, 41-58. https://doi.org/10.1111/ene.13412
|
[2]
|
McFarland, N.R. (2016) Diagnostic Approach to Atypical Parkinsonian Syndromes. CONTINUUM: Lifelong Learning in Neurology, 22, 1117-1142. https://doi.org/10.1212/con.0000000000000348
|
[3]
|
Levin, J., Kurz, A., Arzberger, T., Giese, A. and Höglinger, G.U. (2016) The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärzteblatt international, 113, 61-69. https://doi.org/10.3238/arztebl.2016.0061
|
[4]
|
Miller, N. and Drachman, D.A. (2006) The Optic Nerve: A Window into Diseases of the Brain? Neurology, 67, 1742-1743. https://doi.org/10.1212/01.wnl.0000250233.41910.2f
|
[5]
|
London, A., Benhar, I. and Schwartz, M. (2012) The Retina as a Window to the Brain—From Eye Research to CNS Disorders. Nature Reviews Neurology, 9, 44-53. https://doi.org/10.1038/nrneurol.2012.227
|
[6]
|
La Morgia, C., Ross‐Cisneros, F.N., Koronyo, Y., Hannibal, J., Gallassi, R., Cantalupo, G., et al. (2015) Melanopsin Retinal Ganglion Cell Loss in Alzheimer Disease. Annals of Neurology, 79, 90-109. https://doi.org/10.1002/ana.24548
|
[7]
|
Archibald, N.K., Clarke, M.P., Mosimann, U.P. and Burn, D.J. (2009) The Retina in Parkinson’s Disease. Brain, 132, 1128-1145. https://doi.org/10.1093/brain/awp068
|
[8]
|
Lim, J.K.H., Li, Q., He, Z., Vingrys, A.J., Wong, V.H.Y., Currier, N., et al. (2016) The Eye as a Biomarker for Alzheimer’s Disease. Frontiers in Neuroscience, 10, Article No. 536. https://doi.org/10.3389/fnins.2016.00536
|
[9]
|
Beck, M., Joshi, D.S., Berger, L., Klose, G., De Zanet, S., Mosinska, A., et al. (2020) Comparison of Drusen Volume Assessed by Two Different OCT Devices. Journal of Clinical Medicine, 9, Article No. 2657. https://doi.org/10.3390/jcm9082657
|
[10]
|
Haas, A., Ahmed, D., Stattin, M., Graf, A., Krepler, K. and Ansari‐Shahrezaei, S. (2020) Comparison of Macular Neovascularization Lesion Size by the Use of Spectral‐Domain Optical Coherence Tomography Angiography and Swept‐Source Optical Coherence Tomography Angiography versus Indocyanine Green Angiography. Acta Ophthalmologica, 99, e260-e266. https://doi.org/10.1111/aos.14572
|
[11]
|
Aumann, S., Donner, S., Fischer, J. and Müller, F. (2019) Optical Coherence Tomography (OCT): Principle and Technical Realization. In: Bille, J.F., Ed., High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics, Springer International Publishing, Cham, 59-85. https://doi.org/10.1007/978-3-030-16638-0_3
|
[12]
|
Gilman, S., Wenning, G.K., Low, P.A., Brooks, D.J., Mathias, C.J., Trojanowski, J.Q., et al. (2008) Second Consensus Statement on the Diagnosis of Multiple System Atrophy. Neurology, 71, 670-676. https://doi.org/10.1212/01.wnl.0000324625.00404.15
|
[13]
|
Roncevic, D., Palma, J., Martinez, J., Goulding, N., Norcliffe-Kaufmann, L. and Kaufmann, H. (2013) Cerebellar and Parkinsonian Phenotypes in Multiple System Atrophy: Similarities, Differences and Survival. Journal of Neural Transmission, 121, 507-512. https://doi.org/10.1007/s00702-013-1133-7
|
[14]
|
Papp, M.I., Kahn, J.E. and Lantos, P.L. (1989) Glial Cytoplasmic Inclusions in the CNS of Patients with Multiple System Atrophy (Striatonigral Degeneration, Olivopontocerebellar Atrophy and Shy-Drager Syndrome). Journal of the Neurological Sciences, 94, 79-100. https://doi.org/10.1016/0022-510x(89)90219-0
|
[15]
|
Meissner, W.G., Fernagut, P., Dehay, B., Péran, P., Traon, A.P., Foubert‐Samier, A., et al. (2019) Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders, 34, 1629-1642. https://doi.org/10.1002/mds.27894
|
[16]
|
Jellinger, K.A. (2014) Neuropathology of Multiple System Atrophy: New Thoughts about Pathogenesis. Movement Disorders, 29, 1720-1741. https://doi.org/10.1002/mds.26052
|
[17]
|
Trojanowski, J.Q. and Revesz, T. (2007) Proposed Neuropathological Criteria for the Post Mortem Diagnosis of Multiple System Atrophy. Neuropathology and Applied Neurobiology, 33, 615-620. https://doi.org/10.1111/j.1365-2990.2007.00907.x
|
[18]
|
Beyer, K. and Ariza, A. (2007) Protein Aggregation Mechanisms in Synucleinopathies: Commonalities and Differences. Journal of Neuropathology & Experimental Neurology, 66, 965-974. https://doi.org/10.1097/nen.0b013e3181587d64
|
[19]
|
Armstrong, R.A. (2014) Visual Signs and Symptoms of Multiple System Atrophy. Clinical and Experimental Optometry, 97, 483-491. https://doi.org/10.1111/cxo.12206
|
[20]
|
Leon-Sarmiento, F.E., Bayona-Prieto, J. and Gomez, J. (2005) Neurophysiology of Blepharospasm and Multiple System Atrophy: Clues to Its Pathophysiology. Parkinsonism & Related Disorders, 11, 199-201. https://doi.org/10.1016/j.parkreldis.2004.07.011
|
[21]
|
Anderson, T., Luxon, L., Quinn, N., Daniel, S., David Marsden, C. and Bronstein, A. (2008) Oculomotor Function in Multiple System Atrophy: Clinical and Laboratory Features in 30 Patients. Movement Disorders, 23, 977-984. https://doi.org/10.1002/mds.21999
|
[22]
|
Bremner, F. (2006) Pupil Findings in a Consecutive Series of 150 Patients with Generalised Autonomic Neuropathy. Journal of Neurology, Neurosurgery & Psychiatry, 77, 1163-1168. https://doi.org/10.1136/jnnp.2006.092833
|
[23]
|
Kuroda, M., Fukura, H., Saruki, N., Yoshikawa, D., Morita, T. and Goto, F. (1998) Vecuronium Dose Requirement and Pupillary Response in a Patient with Olivopontocerebellar Atrophy (OPCA). Canadian Journal of Anaesthesia, 45, 979-984. https://doi.org/10.1007/bf03012305
|
[24]
|
Delalande, I., Hache, J., Forzy, G., Bughin, M., Benhadjali, J. and Destée, A. (1998) Do Visual‐Evoked Potentials and Spatiotemporal Contrast Sensitivity Help to Distinguish Idiopathic Parkinson’s Disease and Multiple System Atrophy? Movement Disorders, 13, 446-452. https://doi.org/10.1002/mds.870130312
|
[25]
|
Bak, T.H. (2006) Visuospatial Functions in Atypical Parkinsonian Syndromes. Journal of Neurology, Neurosurgery & Psychiatry, 77, 454-456. https://doi.org/10.1136/jnnp.2005.068239
|
[26]
|
Abele, M., Schulz, J.B., Bürk, K., Topka, H., Dichgans, J. and Klockgether, T. (2000) Evoked Potentials in Multiple Systematrophy (MSA). Acta Neurologica Scandinavica, 101, 111-115. https://doi.org/10.1034/j.1600-0404.2000.101002111.x
|
[27]
|
Fischer, M.D., Synofzik, M., Heidlauf, R., Schicks, J., Srulijes, K., Kernstock, C., et al. (2011) Retinal Nerve Fiber Layer Loss in Multiple System Atrophy. Movement Disorders, 26, 914-916. https://doi.org/10.1002/mds.23523
|
[28]
|
Albrecht, P., Müller, A., Südmeyer, M., Ferrea, S., Ringelstein, M., Cohn, E., et al. (2012) Optical Coherence Tomography in Parkinsonian Syndromes. PLOS ONE, 7, e34891. https://doi.org/10.1371/journal.pone.0034891
|
[29]
|
Mendoza‐Santiesteban, C.E., Palma, J., Martinez, J., Norcliffe‐Kaufmann, L., Hedges, T.R. and Kaufmann, H. (2015) Progressive Retinal Structure Abnormalities in Multiple System Atrophy. Movement Disorders, 30, 1944-1953. https://doi.org/10.1002/mds.26360
|
[30]
|
Mendoza-Santiesteban, C.E., Palma, J., Ortuño-Lizarán, I., Cuenca, N. and Kaufmann, H. (2017) Pathologic Confirmation of Retinal Ganglion Cell Loss in Multiple System Atrophy. Neurology, 88, 2233-2235. https://doi.org/10.1212/wnl.0000000000004020
|
[31]
|
Ahn, J., Lee, J. and Kim, T.W. (2016) Retinal Thinning Correlates with Clinical Severity in Multiple System Atrophy. Journal of Neurology, 263, 2039-2047. https://doi.org/10.1007/s00415-016-8230-0
|
[32]
|
Boxer, A.L., Yu, J., Golbe, L.I., Litvan, I., Lang, A.E. and Höglinger, G.U. (2017) Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches. The Lancet Neurology, 16, 552-563. https://doi.org/10.1016/s1474-4422(17)30157-6
|
[33]
|
Coughlin, D.G. and Litvan, I. (2020) Progressive Supranuclear Palsy: Advances in Diagnosis and Management. Parkinsonism & Related Disorders, 73, 105-116. https://doi.org/10.1016/j.parkreldis.2020.04.014
|
[34]
|
Höglinger, G.U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K.A., Lang, A.E., et al. (2017) Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria. Movement Disorders, 32, 853-864. https://doi.org/10.1002/mds.26987
|
[35]
|
Stamelou, M. (2019) Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 34, 1087-1088. https://doi.org/10.1002/mds.27778
|
[36]
|
Dickson, D.W., Ahmed, Z., Algom, A.A., Tsuboi, Y. and Josephs, K.A. (2010) Neuropathology of Variants of Progressive Supranuclear Palsy. Current Opinion in Neurology, 23, 394-400. https://doi.org/10.1097/wco.0b013e32833be924
|
[37]
|
Kovacs, G.G. (2015) Invited Review: Neuropathology of Tauopathies: Principles and Practice. Neuropathology and Applied Neurobiology, 41, 3-23. https://doi.org/10.1111/nan.12208
|
[38]
|
Lopez, G., Bayulkem, K. and Hallett, M. (2016) Progressive Supranuclear Palsy (PSP): Richardson Syndrome and Other PSP Variants. Acta Neurologica Scandinavica, 134, 242-249. https://doi.org/10.1111/ane.12546
|
[39]
|
Williams, D.R., Holton, J.L., Strand, C., Pittman, A., de Silva, R., Lees, A.J., et al. (2007) Pathological Tau Burden and Distribution Distinguishes Progressive Supranuclear Palsy-Parkinsonism from Richardson’s Syndrome. Brain, 130, 1566-1576. https://doi.org/10.1093/brain/awm104
|
[40]
|
Williams, D.R. and Lees, A.J. (2009) Progressive Supranuclear Palsy: Clinicopathological Concepts and Diagnostic Challenges. The Lancet Neurology, 8, 270-279. https://doi.org/10.1016/s1474-4422(09)70042-0
|
[41]
|
Ling, H., de Silva, R., Massey, L.A., Courtney, R., Hondhamuni, G., Bajaj, N., et al. (2014) Characteristics of Progressive Supranuclear Palsy Presenting with Corticobasal Syndrome: A Cortical Variant. Neuropathology and Applied Neurobiology, 40, 149-163. https://doi.org/10.1111/nan.12037
|
[42]
|
Armstrong, R.A. (2011) Visual Signs and Symptoms of Progressive Supranuclear Palsy. Clinical and Experimental Optometry, 94, 150-160. https://doi.org/10.1111/j.1444-0938.2010.00504.x
|
[43]
|
Valls-Sole, J. (1997) Distinctive Abnormalities of Facial Reflexes in Patients with Progressive Supranuclear Palsy. Brain, 120, 1877-1883. https://doi.org/10.1093/brain/120.10.1877
|
[44]
|
Rivaud-Péchoux, S., Vidailhet, M., Gallouedec, G., Litvan, I., Gaymard, B. and Pierrot-Deseilligny, C. (2000) Longitudinal Ocular Motor Study in Corticobasal Degeneration and Progressive Supranuclear Palsy. Neurology, 54, 1029-1032. https://doi.org/10.1212/wnl.54.5.1029
|
[45]
|
Rascol, O., Sabatini, U., Simonetta-Moreau, M., Montastruc, J.L., Rascol, A. and Clanet, M. (1991) Square Wave Jerks in Parkinsonian Syndromes.. Journal of Neurology, Neurosurgery & Psychiatry, 54, 599-602. https://doi.org/10.1136/jnnp.54.7.599
|
[46]
|
Litvan, I. and FitzGibbon, E.J. (1996) Can Tropicamide Eye Drop Response Differentiate Patients with Progressive Supranuclear Palsy and Alzheimer’s Disease from Healthy Control Subjects? Neurology, 47, 1324-1326. https://doi.org/10.1212/wnl.47.5.1324
|
[47]
|
Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., et al. (2007) Pupil Diameter in Darkness Differentiates Progressive Supranuclear Palsy (PSP) from Other Extrapyramidal Syndromes. Movement Disorders, 22, 2123-2126. https://doi.org/10.1002/mds.21721
|
[48]
|
Rascol, O., Sabatini, U., Fabre, N., Senard, J.M., Simonetta‐Moreau, M., Montastruc, J.L., et al. (1995) Abnormal Vestibuloocular Reflex Cancellation in Multiple System Atrophy and Progressive Supranuclear Palsy but Not in Parkinson’s Disease. Movement Disorders, 10, 163-170. https://doi.org/10.1002/mds.870100206
|
[49]
|
Langheinrich, T., Tebartz van Elst, L., Lagrèze, W.A., Bach, M., Lücking, C.H. and Greenlee, M.W. (2000) Visual Contrast Response Functions in Parkinson’s Disease: Evidence from Electroretinograms, Visually Evoked Potentials and Psychophysics. Clinical Neurophysiology, 111, 66-74. https://doi.org/10.1016/s1388-2457(99)00223-0
|
[50]
|
Cooper, A.D. and Josephs, K.A. (2009) Photophobia, Visual Hallucinations, and REM Sleep Behavior Disorder in Progressive Supranuclear Palsy and Corticobasal Degeneration: A Prospective Study. Parkinsonism & Related Disorders, 15, 59-61. https://doi.org/10.1016/j.parkreldis.2008.01.011
|
[51]
|
Schneider, M., Müller, H., Lauda, F., Tumani, H., Ludolph, A.C., Kassubek, J., et al. (2013) Retinal Single-Layer Analysis in Parkinsonian Syndromes: An Optical Coherence Tomography Study. Journal of Neural Transmission, 121, 41-47. https://doi.org/10.1007/s00702-013-1072-3
|
[52]
|
Stemplewitz, B., Kromer, R., Vettorazzi, E., Hidding, U., Frings, A. and Buhmann, C. (2017) Retinal Degeneration in Progressive Supranuclear Palsy Measured by Optical Coherence Tomography and Scanning Laser Polarimetry. Scientific Reports, 7, Article No. 5357. https://doi.org/10.1038/s41598-017-05575-8
|
[53]
|
Gulmez Sevim, D., Unlu, M., Gultekin, M., Karaca, C., Mirza, M. and Mirza, G.E. (2018) Evaluation of Retinal Changes in Progressive Supranuclear Palsy and Parkinson Disease. Journal of Neuro-Ophthalmology, 38, 151-155. https://doi.org/10.1097/wno.0000000000000591
|
[54]
|
Alkabie, S., Lange, A., Manogaran, P., Stoessl, A.J., Costello, F. and Barton, J.J.S. (2020) Optical Coherence Tomography of Patients with Parkinson’s Disease and Progressive Supranuclear Palsy. Clinical Neurology and Neurosurgery, 189, Article ID: 105635. https://doi.org/10.1016/j.clineuro.2019.105635
|
[55]
|
Chiasseu, M., Alarcon-Martinez, L., Belforte, N., Quintero, H., Dotigny, F., Destroismaisons, L., et al. (2017) Tau Accumulation in the Retina Promotes Early Neuronal Dysfunction and Precedes Brain Pathology in a Mouse Model of Alzheimer’s Disease. Molecular Neurodegeneration, 12, Article No. 58. https://doi.org/10.1186/s13024-017-0199-3
|
[56]
|
Bancher, C., Lassmann, H., Budka, H., Grundke-Iqbal, I., Iqbal, K., Wiche, G., et al. (1987) Neurofibrillary Tangles in Alzheimer’s Disease and Progressive Supranuclear Palsy: Antigenic Similarities and Differences. Microtubule-Associated Protein Tau Antigenicity Is Prominent in All Types of Tangles. Acta Neuropathologica, 74, 39-46. https://doi.org/10.1007/bf00688336
|
[57]
|
Kovacs, G.G., Lukic, M.J., Irwin, D.J., Arzberger, T., Respondek, G., Lee, E.B., et al. (2020) Distribution Patterns of Tau Pathology in Progressive Supranuclear Palsy. Acta Neuropathologica, 140, 99-119. https://doi.org/10.1007/s00401-020-02158-2
|
[58]
|
Seppi, K. (2007) MRI for the Differential Diagnosis of Neurodegenerative Parkinsonism in Clinical Practice. Parkinsonism & Related Disorders, 13, S400-S405. https://doi.org/10.1016/s1353-8020(08)70038-5
|
[59]
|
Savoiardo, M. (2003) Differential Diagnosis of Parkinson’s Disease and Atypical Parkinsonian Disorders by Magnetic Resonance Imaging. Neurological Sciences, 24, s35-s37. https://doi.org/10.1007/s100720300036
|